EcoDrugPlus

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSCATG00000029518
Gene Symbol: TGFBR1
4 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSCATG00000042330
Gene Symbol: TRPA1
4 Cross references
228 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSCATG00000032320
Gene Symbol: TRPM8
4 Cross references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSCATG00000041693
Gene Symbol: TRPV1
4 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Translocator Protein

Ensembl ID : ENSCATG00000031138
Gene Symbol: TSPO
4 Cross references
122 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transthyretin

Ensembl ID : ENSCATG00000033890
Gene Symbol: TTR
4 Cross references
165 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tryptophan Hydroxylase 1

Ensembl ID : ENSCATG00000040162
Gene Symbol: TPH1
4 Cross references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha 1b

Ensembl ID : ENSCATG00000038328
Gene Symbol: TUBA1B
4 Cross references
92 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha 1c

Ensembl ID : ENSCATG00000031924
Gene Symbol: TUBA1C
4 Cross references
130 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha 3e

Ensembl ID : ENSCATG00000031964
Gene Symbol: TUBA3E
3 Cross references
140 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha 4a

Ensembl ID : ENSCATG00000033332
Gene Symbol: TUBA4A
4 Cross references
225 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha-3 Chain

Ensembl ID : ENSCATG00000011034
Gene Symbol: LOC105571676
2 Cross references
105 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).